Literature DB >> 8257151

Susceptibilities to rimantadine of influenza A/H1N1 and A/H3N2 viruses isolated during the epidemics of 1988 to 1989 and 1989 to 1990.

M Valette1, J P Allard, M Aymard, V Millet.   

Abstract

Clinical isolates of influenza A viruses identified during outbreaks in two winters were tested for their rimantadine susceptibilities by an enzyme-linked immunosorbent assay modified from that described previously by Belshe et al. (R. B. Belshe, B. Burk, F. Newman, R. L. Cerruti, and I. S. Sim, J. Virol. 62:1508-1512, 1988). The infectivity titer and the 50% inhibitory concentration of rimantadine were calculated for each virus. Of 105 influenza virus A isolates tested, 28 influenza A/H1N1 isolates from the 1988 and 1989 outbreak and 77 influenza A/H3N2 isolates from the outbreak in following year, were susceptible to the antiviral action of rimantadine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257151      PMCID: PMC192258          DOI: 10.1128/AAC.37.10.2239

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance.

Authors:  R B Belshe; B Burk; F Newman; R L Cerruti; I S Sim
Journal:  J Infect Dis       Date:  1989-03       Impact factor: 5.226

2.  Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

Authors:  R B Belshe; M H Smith; C B Hall; R Betts; A J Hay
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

3.  A rapid and automated colorimetric assay for evaluating the sensitivity of herpes simplex strains to antiviral drugs.

Authors:  M Langlois; J P Allard; F Nugier; M Aymard
Journal:  J Biol Stand       Date:  1986-07

4.  Molecular basis of resistance of influenza A viruses to amantadine.

Authors:  A J Hay; M C Zambon; A J Wolstenholme; J J Skehel; M H Smith
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

5.  Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults.

Authors:  F G Hayden; A S Monto
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

6.  Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults.

Authors:  F G Hayden; A Minocha; D A Spyker; H E Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics.

Authors:  F G Hayden; H E Hoffman; D A Spyker
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

8.  Plaque inhibition assay for drug susceptibility testing of influenza viruses.

Authors:  F G Hayden; K M Cote; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

9.  Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.

Authors:  F G Hayden; R B Belshe; R D Clover; A J Hay; M G Oakes; W Soo
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

  9 in total
  3 in total

1.  Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.

Authors:  J Iwahashi; K Tsuji; T Ishibashi; J Kajiwara; Y Imamura; R Mori; K Hara; T Kashiwagi; Y Ohtsu; N Hamada; H Maeda; M Toyoda; T Toyoda
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.

Authors:  Donald F Smee; Justin G Julander; E Bart Tarbet; Matthew Gross; Jack Nguyen
Journal:  Antiviral Res       Date:  2012-07-15       Impact factor: 5.970

3.  African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses.

Authors:  E A Govorkova; G Murti; B Meignier; C de Taisne; R G Webster
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.